Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
The interdisciplinary field of regenerative medicine – comprised of tissue engineering (TE), cell therapy (CT), and gene therapy (GT) – is growing rapidly, characterized by groundbreaking therapeutic advances that have the potential to change how healthcare providers deliver care.
By Lev Gerlovin, Andrew Thomson, and Jack Vailas, Life Sciences Practice, CRA The regenerative medicine sector, comprised of tissue engineered products and cell and gene therapies, has grown rapidly over the past decade, including significant therapeutic advances that offer the prospect of optimizing and transforming patient care.
Advances in DNA technologies have uncovered a new subspecies of red-tailed black-cockatoo in Western Australia by GrrlScientist for Forbes | @GrrlScientist NOTE: This piece was a Forbes Editor’s pick. When recognising a new species or subspecies, a “holotype” (i.e., the specimen from which the subspecies or species was first described) is required. The holotype for Calyptorhynchus banksii escondidus is a specimen held at CSIRO’s Australian National Wildlife Collection (ANWC), specimen ANWC B37847.
Bioprinted organs soon could revolutionize clinical trials, transplantation, and regenerative medicine. But as Chris Lo reminds us in a new GlobalData report (1), several technical hurdles must be negotiated before biopharmaceutical companies can harness three-dimensional (3D) bioprinting for such purposes.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
